Welcome to University of Mumbai, Department of Biophysics

Bioinformatics Database on
"Radiosensitisers and Radioprotectors"

Alphabetical Search   >  P   >  Probucol                                                                                                                                                                 Top


Go To:

General Features                  Clinical Study                  Chemical Intervention                 Pharmacological Aspects                 
Radiobiological Aspects                  Biological Models                  Biological Target                  Toxicity                 


Name: Probucol
Trade name: Powdered probucol(Lorelco)[1]
Chemical name: 4,4'-isopropylidenedithio-bis-(2,6-di-tert-butylphenol)[2]
Molecular Weight: 516.84 g/mol[2]
Source: Probucol is a synthetic drug synthesized at Dow Chemical[3]
Structure: [2],[4],[5]
Chemical Nature: Melting Point 125-128oC [2]
lipophilic phenolic compound[2]
very soluble in acetone, chloroform and dimethylformate, soluble in ethanol, ether and carbon tetrachloride, insoluble in water[2]
& Indications:
Pharmcological Action-
anti-atherogenetic in rats[6]
Therapeutic indications:
probucol is used for the treatment for hypercholesterolemia, being particularly effective in patients with a combined increase of LDL-C and HDL-C levels[8]
Preclinical study-
1. Bonsack ME et al, Radioprotection of the intestinal mucosa of rats by Probucol. Radiation Research. 1999;151(1):69-73.
2. 6 : Antioxidants Properties of Probucol by Niki E, Noguchi N ; In : Part III : Phenolic Antioxidants; In : Handbook of Synthetic Antioxidants, edited by Packer L, Cadenas E, CRC Press, 1997, Page no. 226-227.
3. 8 : Probucol by Steinberg D, Witztum JL ; In : Drug Treatment of Hyperlipidemia, edited by Rifkind BM, CRC Press, 1991, page no. 175.
4. Araki T, Kitaoka H, Antioxidative properties of Probucol estimated by the reactivity with superoxide and by electrochemical oxidation. Chem. Pharm. Bull. 2001;49(8) :943—947.
5. Buckley MM et al, Probucol. A reappraisal of its pharmacological properties and therapeutic use in hypercholesterolaemia. Drugs. 1989 ;37(6):761-800.
6. Eisenberg S, The effects of probucol on the levels, structure, composition and metabolism of plasma lipoprotein in rats. Biochim Biophys Acta. 1993;1167(1):79-84.
7. Bonnefont-Rousselot D et al, Antioxidant effect of Probucol on RO2·/O2·-induced peroxidation of human low-density lipoproteins. Radiat. Res. 1999;151(3):343-353.
8. Baldassarre D et al, Clinical evaluation of probucol in hypercholesteremia: individual lipoprotein responses and inhibitory effect on carotid atherosclerosis progression. J Cardiovasc Pharmacol. 1997;30(6):7849